FDA's compounded GLP-1 enforcement in 2026: what 55+…

An FDA warning letter is a formal communication to a company or individual identifying specific violations of FDA regulations. Warning letters are public — FDA publishes them on its website — and they carry legal significance: recipients are expected to respond and correct the violations.

Warning letters are not criminal charges. They do not prove individual patients were harmed. They document what FDA found during a review of a company's marketing materials, labeling, or practices, and they require corrective action.

In the case of telehealth companies marketing compounded GLP-1s, the violations FDA documented were primarily marketing violations — specific claims made on websites and in promotional materials.

The FDA's March 2026 press release described the 30 warning letters as addressing companies that made "false or misleading claims" regarding compounded GLP-1 products. The specific violation types FDA identified include:

• Implying sameness with FDA-approved products: Some companies' materials suggested their compounded semaglutide or tirzepatide was equivalent in safety and quality to the FDA-approved branded versions. Compounded drugs are not FDA-approved. Quality, sterility, and concentration may differ.
• Unapproved branding without disclosure: Some companies branded their compounded products without making clear these were compounded preparations, not the approved branded drugs.
• False efficacy or safety claims: Some materials overstated clinical evidence or implied the compounded formulations were proven safe and effective in ways that the evidence does not support.

The FDA's guidance page for telehealth companies — "What to Know When Promoting Compounded Drugs" — outlines these standards in detail.

As of May 21, 2026, FDA had received more than 1,700 adverse event reports associated with compounded semaglutide and tirzepatide. This figure comes from the FDA Adverse Event Reporting System (FAERS), which accepts voluntary reports from patients, healthcare providers, and manufacturers.

Adverse event reports are not confirmed diagnoses of drug-caused harm. FAERS captures reports of events that occurred in patients who were taking a drug — not proof that the drug caused the event. The system is designed to identify signals that warrant further investigation, not to determine causation.

What the 1,700+ number does signal is that compounded GLP-1 use at scale has been associated with a volume of reported problems — including, according to the Sheppard Mullin legal analysis, dosing errors from multidose vials that required hospitalization.

Dosing errors from multidose vials are a known risk specific to compounded injectable preparations. FDA-approved branded GLP-1s come in fixed-dose auto-injectors designed to reduce dosing error. Compounded preparations in vials require the patient or a caregiver to draw the correct dose — a step that carries more opportunity for error.

The enforcement activity does not mean everyone who used a compounded GLP-1 was harmed. Most people who used these products did not experience a serious adverse event.

What the enforcement record does tell you: the marketing claims many companies made were not accurate or were legally impermissible; the quality, sterility, and concentration of compounded GLP-1s varied by pharmacy; and the compounding pathway these products used was legal only under shortage conditions — conditions that have now changed.

If you received a warning letter notice from your telehealth company, or if your access to a compounded GLP-1 has changed, talk to your prescriber before stopping or adjusting your medication. Stopping a GLP-1 without a plan — particularly if you have obesity or a related cardiometabolic condition — carries its own risks.

Legitimate telehealth prescribing of GLP-1 medications exists and is legal. FDA-approved GLP-1 drugs can be prescribed via telehealth, just as they can in person. The enforcement actions target companies that misrepresented their compounded products — not telehealth prescribing generally.

If you are seeking a GLP-1 via telehealth, the relevant questions are: Is this an FDA-approved drug being dispensed by a licensed pharmacy? Is the company's prescribing process compliant with your state's telehealth laws? Is the company making specific claims about its products being equivalent to the FDA-approved branded version?

The FDA has indicated it is continuing to monitor the compounding space and may issue additional enforcement actions. The extent to which adverse events from compounded GLP-1s will result in additional regulatory restrictions on formulations or administration forms is not yet determined.

• Is my current GLP-1 prescription for an FDA-approved drug or a compounded preparation?
• If my telehealth company received a warning letter, what does that mean for my prescription access?
• What transition options are available if my current compounded GLP-1 is no longer available?

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• FDA press release — 30 warning letters, March 2026: fda.gov
• FDA guidance — What to Know When Promoting Compounded Drugs: fda.gov
• Sheppard Mullin legal analysis — FDA compounding and telehealth enforcement, June 2026: sheppard.com